The decision by Australia’s drug regulator to allow authorised psychiatrists to prescribe psychedelic drugs is “questionable, if not concerning”, and likely driven by the influence of lobby groups instead of health experts, mental health researchers say.
As of 1 July, authorised psychiatrists have been able to prescribe medicines containing psilocybin for treatment-resistant depression, and MDMA for post-traumatic stress disorder. The decision by the Therapeutic Goods Administration followed public consultation, a report from an expert panel and advice received from a medicine advisory committee.
